Home
Science
Therapeutic Strategy
Team
News
Contact

Contact

Recent Posts

Visgenx To Present At Eyecelerator At The American Academy Of Ophthalmology Annual Meeting 2024
Visgenx Announces Presentation of Data Supporting Potential of its Synthetic AAV DNA Platform for Gene Editing at ASGCT
ASGCT 2024 Poster Abstract
ELOVL2 Enzyme Product Improves Retinal Function and Rejuvenates Retina Architecture in an Aged Mouse Model of AMD
Visgenx to Present at the Second Annual 2024 Cell & Gene Therapy Summit

Archives

October 2024
May 2024
April 2024
December 2023
November 2023
October 2023
September 2023
June 2023
May 2023

Categories

Uncategorized

Archives

October 2024
May 2024
April 2024
December 2023
November 2023
October 2023
September 2023
June 2023
May 2023

Month: June 2023

29.06.2023

Visgenx Announces Positive Results from a Key Translational Study for its Gene...

»

05.06.2023

Visgenx Appoints William Pedranti as Chief Executive Officer

»

Visgenx, Inc. © 2024. All Rights Reserved.

Privacy Policy Terms of Use

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy